PTC grabs $10M milestone; Sarepta scales up eteplirsen manufacturing as it preps for '14 NDA;

@FierceBiotech: Ousted scientist fires back at GSK's high-pressure R&D strategy in China. Story | Follow @FierceBiotech

@JohnCFierce: Is the silly season on biotech IPOs over? No, Intrexon debuts with $2B market value. Item | Follow @JohnCFierce

@RyanMFierce: Biotech M&A gossip: Amgen buyout of Onyx could happen soon. More | Follow @RyanMFierce

@EmilyMFierce: NIH to open genomic data of HeLa cells to researchers. Article | Follow @EmilyMFierce

> PTC Therapeutics ($PTCT) snagged a $10 million milestone following the selection of a development candidate in its spinal muscular atrophy collaboration with Roche ($RHBBY) and the SMA Foundation. Release

> Cambridge, MA-based Sarepta Therapeutics ($SRPT) says it is ramping up its manufacturing of eteplirsen as it prepares to seek an accelerated approval for the Duchenne muscular dystrophy therapy in the first half of 2014. Release

> Silence Therapeutics says that it has dosed the first patients with pancreatic cancer in a Phase IIa study of Atu027. Story

Medical Device News

@FierceMedDev: Alere declares victory in proxy challenge. Article | Follow @FierceMedDev

@DamianFierce: Losses mounting, Invacare sells off another unit for $45M. Story | Follow @DamianFierce

@MichaelGFierce: Luminex axing 5% of workforce as reimbursement dries up. Article | Follow @MichaelGFierce

> CareFusion saddled with yet another Class I recall. More

> SetPoint snags $27M from GSK, Covidien. Story

> Thermo lops off 240 jobs as it preps for Life Tech merger. Article

Pharma News

@FiercePharma: Tyson suspends use of Merck growth enhancer for cattle b/c some having difficulty walking. Merck says Zilmax safe. Item | Follow @FiercePharma

@CarlyHFierce: ICYMI: On Vivus' Q2 earnings and plans from new CEO Tony Zook (formerly of AstraZeneca) to increase Qsymia sales. More | Follow @CarlyHFierce

> Sanofi faces bribery allegations from China whistleblower. Story

> Wanted: Buyers for Aptalis Pharma. Must be willing to pay $3B-plus. Article

> Endo invests big in Qualitest to push generic growth. More

Vaccines News

> Flu vaccine tablet developer raises $20M. News

> PharmAthene to add antibody assets in Theraclone merger. Item

> Sanofi advances C. diff vaccine into PhIII. More

> Israel buys 500,000 polio vaccines for immunization push. Article

> GSK adding 2-D barcode to 4-in-1 flu vaccine packaging. Story

> Dana-Farber sees promise in leukemia vaccine trial. More

Pharma Manufacturing News

@EricPFierce: Pharma Tech Industries to expand facility in Missouri Story | Follow @EricPFierce

> GAO report says FDA needs clear authority over compounders. News

> Ranbaxy gets site for second Malaysian plant. Story

> When it comes to Viagra, counterfeiters just can get enough. Article

> Endo investing $100M in Qualitest manufacturing. More

> Recall expert takes services to Europe. Item

And Finally… A new study failed to show that probiotics could ward off diarrhea caused by antibiotics in elderly patients. Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.